Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fera Pharmaceuticals (Fera) has reported that Bacitracin Ophthalmic ointment, USP is now available through wholesalers, chain, independent and hospital pharmacies.
Subscribe to our email newsletter
The company claims that Bacitracin Ophthalmic ointment, USP is the first product transfer to be completed. It is anticipated that the transfer of Erythromycin Ophthalmic ointment is expected to occur in the next few weeks at which point Fera would ship immediately.
Reportedly, the manufacturing transfer for the balance of the line is underway with availability projected later in the year.
Frank DellaFera, president of Fera, said: “The company has been diligently working to transfer manufacturing of these products in order to meet market demand for these important sterile anti-infective ointments.”
In July 2009, Fera has acquired all rights and title to seven ophthalmic ointments, including Bacitracin. Product supply has been an issue since then, as the previous owner had discontinued manufacture of Bacitracin and only a limited quantity was made available during the transition to Fera.